Ripretinib showed lower potency against the KIT D816V (exon 17) mutation as compared to avapritinib while exhibiting the greatest potency against the KIT exon 18 A829P mutation amongst the FDA-approved drugs for GIST [12]. Here, KIT is linked to gastrointestinal stromal tumor.